Skip to Content

Alterity Therapeutics Ltd ADR ATHE

Morningstar Rating
$1.77 0.00 (0.00%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

ATHE is trading at a 642% premium.
Price
$1.77
Fair Value
$1.43
Uncertainty
Extreme
1-Star Price
$311.45
5-Star Price
$4.73
Economic Moat
Vsy
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ATHE is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$1.77
Day Range
$1.751.79
52-Week Range
$1.555.41
Bid/Ask
$1.75 / $1.89
Market Cap
$15.45 Mil
Volume/Avg
13,424 / 75,259

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Alterity Therapeutics Ltd is active in the healthcare domain. The company is engaged in research collaborations for the treatment of Parkinsonian movement disorders, Alzheimer's disease, Huntington disease, and other neurodegenerative disorders. The company's lead drug candidate-PBT2 is being developed for the treatment of Alzheimer's and Huntington's diseases. It has also advanced a drug candidate for Parkinson's disease and other movement disorders (ATH434). The Group operated in one segment, being researching and developing Parkinsonian and other neurodegenerative disorders.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
11

Valuation

Metric
ATHE
Price/Earnings (Normalized)
Price/Book Value
0.58
Price/Sales
Price/Cash Flow
Price/Earnings
No chart available

Financial Strength

Metric
ATHE
Quick Ratio
5.58
Current Ratio
6.17
Interest Coverage
Quick Ratio
ATHE

Profitability

Metric
ATHE
Return on Assets (Normalized)
Return on Equity (Normalized)
Return on Invested Capital (Normalized)
Return on Assets
ATHE
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk A/S ADR
NVO
RrzbbbpxmpWrhw$631.5 Bil
Vertex Pharmaceuticals Inc
VRTX
TwvqprtlFfwstxt$121.0 Bil
Regeneron Pharmaceuticals Inc
REGN
DvzdydvpFwxzzy$116.0 Bil
Moderna Inc
MRNA
FylkxlrpXgfds$51.1 Bil
argenx SE ADR
ARGX
KgzdfdckYpxb$23.7 Bil
Alnylam Pharmaceuticals Inc
ALNY
HmczbrncPslsdpt$21.0 Bil
BioNTech SE ADR
BNTX
CmyfhtzyFlxp$20.4 Bil
Biomarin Pharmaceutical Inc
BMRN
LgxjvqsqXznpg$15.9 Bil
United Therapeutics Corp
UTHR
TncbcxplcPcz$14.0 Bil
Incyte Corp
INCY
NyhnbxdJqhwcjq$12.5 Bil

Sponsor Center